Idenix Pharmaceuticals (IDIX) CEO Won't Comment on Takeover Speculation, Shares Dip
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Idenix Pharmaceuticals Inc. (Nasdaq: IDIX) CEO won't comments on takeover speculation during CNBC interview. He said the company is aware of the M&A activity around them but is focused on their work in the Hep-C space.
Shares are dipping a little lower now that interview is over - now up just 1%.
Shares are dipping a little lower now that interview is over - now up just 1%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Holcim said to acquire part of James Hardie's EU business
- Apple Cuts Jobs in Siri, Vision Pro 3D Video and Gaming Teams - Bloomberg
Create E-mail Alert Related Categories
Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
